Obecabtagene autoleucel (NCT07053059)

Name: Obecabtagene autoleucel trial for Acute Lymphocytic Leukemia (ALL) (NCT07053059)
Uploaded: 2026-10-31T16:50:23.089Z
Duration: 1 min 27 s
Description: Obecabtagene autoleucel trial for Acute Lymphocytic Leukemia (ALL) (NCT07053059). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07053059.

Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL): a one-minute explainerNCT070530591 min

Obecabtagene autoleucel trial for Acute Lymphocytic Leukemia (ALL) (NCT07053059). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with high-risk B-cell acute lymphoblastic leukemia in first remission, with fewer than five percent marrow blasts and CD19 expression above 1%. Philadelphia-positive or Philadelphia-negative disease can qualify.

The idea: obecabtagene autoleucel uses the patient's modified T cells to target CD19-bearing cells. It is infused as consolidation after initial treatment. Researchers assess event-free survival at 18 months, residual leukemia, and safety. Controlled central-nervous-system or disease outside marrow is allowed.

This phase 2 study plans 30 patients. Elias Jabbour leads at MD Anderson in Houston, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.